Comparison of the effect of cyclosporine and etanercept on Toxic epidermal necrolysis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191020045169N1

Enrollment

Registered

2020-02-14

Start date

2020-03-20

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

toxic epidermal necrolysis. Toxic epidermal necrolysis [Lyell]

Interventions

Intervention 1: Intervention group: toxic epidermal necrolysis patients, treated with etanercept 50mg(Ariogen pharmed) single dose subcutaneously on their first day of admission. Intervention 2: Inter

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with toxic epidermal necrolysis confirmed by a dermatologist.

Exclusion criteria

Exclusion criteria: patients with any acquired or congenital immune deficiency. patients with stage 3 or 4 of heart failure. patients with uncontrolled hypertension. patients with renal failure. patients with known hypersensitivity to these drugs.

Design outcomes

Primary

Measure	Time frame
Leisions re-epithelialization of the toxic epidermal necrolysis. Timepoint: daily, during patients admission. Method of measurement: by dermatologist examination and taking standard pictures from patients lesions.	—

Secondary

Measure	Time frame
Mortality rate of the patients. Timepoint: During their admission in the hospital. Method of measurement: SCORTEN index.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnaz Araghi

Shahid Beheshti University of Medical Sciences

farnazaraghi@sbmu.ac.ir+98 21 5541 9005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026